QUOTE AND NEWS
Benzinga  Mar 30  Comment 
P&F Industries Inc. (NASDAQ: PFIN) shares fell 11.28% to reach a new 52-week low of $6.84 after the company reported Q4 earnings of $0.56 per share on revenue of $17.9 million. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares dipped 3.21% to...
TheStreet.com  Mar 23  Comment 
NEW YORK (TheStreet) -- What looked like a smart play turned to disaster as biotech stock AcelRX Pharmaceuticals is now hovering around $4 a share, down from around $9 a share in the beginning of March.  Trouble with FDA clinical trials and...
Benzinga  Mar 10  Comment 
Analysts at Jefferies downgraded AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) from Buy to Hold. The price target for AcelRx Pharmaceuticals has been lowered from $12.00 to $6.00. AcelRx Pharmaceuticals shares have dropped 53.70% over the past...
Benzinga  Mar 10  Comment 
Benzinga  Mar 10  Comment 
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) extended its losses in after-hours trading Monday after the company said it won't submit a new drug application in the current quarter for its lead drug candidate, pain medication Zalviso. AcelRx...
TheStreet.com  Mar 9  Comment 
NEW YORK (TheStreet) -- AcelRx Pharmaceuticals shares are down 34.67% to $5.71 in early market trading on Monday after the company announced that the FDA is demanding another clinical trial for its pain pill Zalviso.As a result of the request...
Benzinga  Mar 9  Comment 
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares tumbled 35.01% to $5.68. AcelRx received an FDA update regarding the NDA application for Zalviso. Sky-mobi Limited (NASDAQ: MOBI) shares fell 12.76% to $4.17. Sky-mobi reported Q4 earnings of...
TheStreet.com  Jan 15  Comment 
NEW YORK (TheStreet) -- Last July, AcelRx Pharmaceuticals was hit with an FDA rejection of its painkiller dispensing device Zalviso. Not surprisingly, AcelRx shares sank on the bad news, but Zalviso is expected to be resubmitted for a second...




 
TOP CONTRIBUTORS

AcelRx (NASDAQ:ACRX) is a pharmaceutical company which develops and sells treatments for acute and breakthrough pain. In particular, the product would help with post-operative pain. AcelRx has completed Phase 2 and is preparing to conduct two Phase 3 clinical trials for its lead product.[1]

Acute and breakthrough pain associated with the post-operation period is often treated with intravenous (IV) opioid injections. These tend to have negative side effects due to the usage of morphine. In addition, there can be delivery and programming errors from the complex infusion pumps used to provide the patients with the opioid. AcelRx's lead candidate involves a patient administered dosage sublingual, or below the tongue. AcelRx also uses Sufentanil rather than morphine.[2]

The company's initial public offering of stock on the NASDAQ occurred on February 10, 2011. The company offered 8M shares each for $5. The company originally planned to sell 5.8M shares within the range of $12-$14. This would have made the deal worth $75.4M, but the drop in price brought the total deal to $40M even after the rise in shares sold. The lead underwriter of the deal was Piper Jaffray Companies (PJC). Canaccord Capital (BER:C6U), Cowen Group (COWN), and JMP Group (JMP) acted as comanagers.[3]

Because AcelRx does not have a commercially viable yet, the company is still in the pre-revenue stage. As a result, the company has incurred high Research & Development expenses without making money. For the first 9 months of 2010, AcelRx's net loss was $10.8M, 58% of which was from research and development expenses. [4]

References

  1. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg1
  2. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Sufentanil NanoTabs" pg1-2
  3. Renaissance Capital - IPO Home "AcelRx prices IPO at $5, below the original $12-$14 range" 11 Feb 2011
  4. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Summary Financial Data" pg10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki